ArticleOphthalmology and therapy2026
Half-Dose Photodynamic Therapy for Bullous Variant Central Serous Chorioretinopathy: A Long-Term Follow-Up.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo evaluate the long-term outcomes of half-dose half-dose photodynamic therapy (PDT) in the treatment of bullous variant central serous chorioretinopathy (bvCSC).
methodsA retrospective single-center study of 18 patients, 31 eyes with bvCSC who received PDT between January 2012 and December 2021 with a minimum follow-up of 36 months.
resultsDuring follow-up, a dry macula was achieved in all cases and no recurrence was witnessed. The mean number of PDT treatments was 1.2 sessions. Twenty-five (80.6%) eyes in 14 patients achieved complete fluid resolution after a single session. The earliest complete resolution of subretinal fluid occurred at 1 month, while the latest was at 12 months, with a mean time of 4.2 months. The subretinal fibrinous exudates were completely resolved in all affected eyes, with the earliest resolution observed at 1 month and the latest at 13 month, with an average time of 5.9 months. In seven (22.6%) eyes with pre-existing conditions, the subretinal fibrosis and scarring remained unchanged. The baseline average logMAR BCVA was 1.08 ± 0.55, and it improved to 0.74 ± 0.80 at final visit (P < 0.001), with visual gain stabilizing at 24 months. One eye (3.2%) with defects in the retinal pigmentary epithelium-choriocapillaris developed choroidal neovascularization 10 months after treatment.
conclusionsOur clinical data suggested half-dose PDT might offer a favorable safety and efficacy profile in treating conventional bvCSC, with visual gain stabilizing at 24 months post-treatment. Cautious risk-benefit assessment remains essential for patients with high-risk ischemic anatomical features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.